WALSH COLIN
SEC CIK 1866174 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ATTO | Attovia Therapeutics, Inc. | Dir | 3.02M | $20.57M | $4.50M | 6 | 2026-08-05 | 2026-08-06 |
Most active insiders at ATTO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | WALSH COLIN | Dir | $20.57M | $4.50M |
| 2 | Redmile Group, LLC | 10% | $10.20M | — |
| 3 | Frazier Life Sciences XI, L.P. | 10% | $10.00M | — |
| 4 | venBio Global Strategic Fund IV, L.P. | 10% | $6.50M | — |
| 5 | Sanofi | 10% | $5.10M | — |
| 6 | Deep Track Biotechnology Master Fund, Ltd. | 10% | — | — |
Transactions 6
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMAI | 2026-08-28 17:38 | 2026-08-05+ | ATTO | Attovia Therapeutics, Inc. | WALSH COLIN | Dir | P - Purchase | $17.58 | +585.0K | 3.02M | +24% | +$10.29M |
| DMAI | 2026-08-28 17:38 | 2026-08-05 | ATTO | Attovia Therapeutics, Inc. | WALSH COLIN | Dir | S - Sale | $21.28 | -105.8K | 0 | -100% | -$2.25M |
| DMAI | 2026-08-28 17:38 | 2026-08-06 | ATTO | Attovia Therapeutics, Inc. | WALSH COLIN | Dir | C - Cnv Deriv | $0.00 | +2.44M | 2.52M | +2,865% | $0 |
| DMI | 2026-08-13 21:52 | 2026-08-05+ | ATTO | Attovia Therapeutics, Inc. | WALSH COLIN | Dir | P - Purchase | $17.58 | +585.0K | 3.02M | +24% | +$10.29M |
| DMI | 2026-08-13 21:52 | 2026-08-05 | ATTO | Attovia Therapeutics, Inc. | WALSH COLIN | Dir | S - Sale | $21.28 | -105.8K | 0 | -100% | -$2.25M |
| DMI | 2026-08-13 21:52 | 2026-08-06 | ATTO | Attovia Therapeutics, Inc. | WALSH COLIN | Dir | C - Cnv Deriv | $0.00 | +2.44M | 2.52M | +2,865% | $0 |
Purchase Sale Sale after option exercise All abbreviations